Use of melvidalin and other D1 positive allosteric modulators in treatment of hallucination and dementia-related psychosis

The present invention relates to methods of treatment and dosing regimens for the treatment of hallucination and/or psychosis using Mevidaline, also described as 2-(2, 6-dichlorophenyl)-1-[(1S, 3R)-3-(hydroxymethyl)-5-(3-hydroxy-3-methylbutyl)-1-methyl-3, 4-dihydroisoquinolin-2 (1H)-yl] ethanone, and/or pharmaceutical compositions thereof, in particular for the treatment of hallucination and/or psychosis. The hallucination and/or psychosis includes dementia-associated psychosis. 本发明涉及使用美维达林，也描述为2-(2,6-二氯苯基)-1-[(1S,3R)-3-(羟甲基)-5-(3-羟基-3-甲基丁基)-1-甲基-3,4-二氢异喹啉-2(1H)-基]乙酮和/或其药物组合物来治疗幻觉和/或精神病的治疗方法和给药方案，该幻觉和/或精神病包括痴呆相关的精神病。